Research Analysts Issue Forecasts for Amgen FY2027 Earnings

Amgen Inc. (NASDAQ:AMGN) – Stock analysts at Erste Group Bank dropped their FY2027 earnings per share estimates for shares of Amgen in a research report issued on Wednesday, July 15th. Erste Group Bank analyst H. Engel now forecasts that the medical research company will post earnings per share of $23.58 for the year, down from their prior forecast of $23.62. Erste Group Bank currently has a “Hold” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $22.31 per share.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same period in the previous year, the firm earned $4.90 earnings per share. Amgen’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS.

A number of other equities research analysts also recently issued reports on the stock. Argus reduced their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research note on Wednesday, May 20th. Morgan Stanley lowered their price objective on shares of Amgen from $340.00 to $333.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 8th. Mizuho boosted their price target on shares of Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 16th. Wells Fargo & Company boosted their target price on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 19th. Finally, The Goldman Sachs Group set a $389.00 target price on shares of Amgen in a report on Friday, June 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Amgen has an average rating of “Hold” and an average target price of $356.62.

Amgen Trading Up 3.7%

AMGN opened at $371.58 on Friday. The business’s 50 day moving average price is $347.00 and its 200 day moving average price is $350.27. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The stock has a market capitalization of $200.55 billion, a PE ratio of 25.86, a P/E/G ratio of 3.63 and a beta of 0.41. Amgen has a one year low of $269.77 and a one year high of $391.29.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.85% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. High Note Wealth LLC boosted its holdings in Amgen by 5.8% during the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock worth $166,000 after buying an additional 28 shares in the last quarter. TAGStone Capital Inc. increased its holdings in Amgen by 0.7% in the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after buying an additional 28 shares in the last quarter. Verus Capital Partners LLC lifted its position in shares of Amgen by 2.3% during the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after acquiring an additional 28 shares during the period. Destination Wealth Management lifted its position in shares of Amgen by 2.1% during the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after acquiring an additional 29 shares during the period. Finally, Breakwater Capital Group boosted its stake in shares of Amgen by 1.4% during the 1st quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company’s stock worth $717,000 after acquiring an additional 29 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.